- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00214708
Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?
Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis? A Cluster Randomised Controlled Trial in an East London Primary Care Trust
This randomised controlled trial tests whether screening people registering with general practices cost-effectively increases the detection of tuberculosis. The study objectives are to:
- recruit, and randomise with stratification, forty Hackney general practices to usual activity or screening for TB primarily during registration health checks (by practice nurses and GPs) and transfer-in visits for children (by health visitors)
- implement a screening programme comprising education, resources and clinical support for intervention practices using proven behaviour change strategies
- gather outcomes and costs
- build research capacity within an ELENoR Primary Care Research Team and across a Primary Care Trust.
The primary outcome is the proportion of TB cases identified in primary care. The study is powered to detect a 20% increase (from 55% to 75%) in the detection of new cases of TB in primary care with 80% power at the 5% significance level. Secondary outcomes are rates of prophylaxis for latent TB infection (LTBI), BCG immunisation, smear negative (early) TB and costs. Analyses will be by intention to treat.
Přehled studie
Detailní popis
To date, studies of screening for tuberculosis have used relatively weak designs. A randomised trial would give stronger evidence as to whether screening is worthwhile and therefore would be welcome. We have tested the feasibility of screening in two general practices in Hackney; our results suggest that it is simple and straightforward, that the people screened were comfortable taking part, and that screening does indeed identify people with tuberculosis.
How (or indeed whether) to screen for tuberculosis constitutes a major policy issue for inner city public health care. Our work will go some way toward answering this important question and will have local, national and international relevance. There are important benefits for those taking part. First, the project is part of a local health development scheme which encourages GPs to register refugees and asylum seekers. This means that a group of people who find it difficult to get health care will be more likely to be able to find a GP. Second, people registering with general practices who are screening will all have a brief discussion about tuberculosis when they attend a health check at the surgery. This will make people more informed about tuberculosis and help to remove the stigma that attends tuberculosis. Third, screening is likely to identify people with tuberculosis, or who need BCG vaccination to prevent tuberculosis. These people will benefit from early treatment or immunisation.
We will invite all general practices in Hackney to take part. Practices that agree will then be randomly allocated (by a computer programme) into two groups: practices who will screen and those who will carry on as usual without screening. The project researcher responsible for data collection will not know to which group the practices have been assigned. Practices allocated to the screening group will be offered a programme designed to encourage screening as part of the new patient registration checks (by practice nurses and GPs) and during children's transfer-in visits (by health visitors). The programme is founded on proven ways of helping people change how they work and includes the following: an education programme run by the primary care research team, with a local chest consultant as opinion leader; Heaf guns, Heaf heads, and tuberculin (to test for presence of TB); TB screening guidelines; regular support and advice from the local TB specialist nurse; incorporation of a TB screening template into the practice computer consulting system; and an incentive fee paid to the practices for carrying out the Heaf tests. TB identication rates for both groups will be ascertained after 25 months of screening. The cost of implementing the screening process will also be measured.
Patients / public involvment (subjects and partners):
People attending for new registration checks and children seen at transfer-in visits are the study participants. They will be informed about the study (using information sheets in various languages); they can decline to take part if they like. Public involvement in the design and execution of the study comes in three forms. First, the East London Refuge and Asylum seeker worker has contributed to the study design and will be involved throught the study. Second, the work is part of an East London Health Improvement Plan, which itself has public support. Third, the study has approval from the East London and Esssex Network of Researchers' Research Advisory Committee, which has two consumer representatives
Typ studie
Zápis
Kontakty a umístění
Studijní místa
-
-
-
London, Spojené království, E9
- City and Hackney
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
The intervention is screening for TB in general practices which were randomised to control or intervention
Exclusion Criteria:
Practices that refused to participate could not be included. We excluded the general practice where the pilot study was undertaken
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Definovaná populace
- Časové perspektivy: Budoucí
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Chris J Griffiths, DPhil, MB BS, Queen Mary University of London
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- TB-02-04-CG
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Tuberkulóza
-
University Children's Hospital BaselUniversity Hospital, Geneva; University Hospital Inselspital, Berne; Kantonsspital... a další spolupracovníciNábor
-
National Institute of Allergy and Infectious Diseases...DokončenoMycobacterium tuberculosisBrazílie
-
The University of Texas Health Science Center,...National Institute of Allergy and Infectious Diseases (NIAID)DokončenoMycobacterium tuberculosisSpojené státy, Kolumbie, Mexiko
-
National Institute of Allergy and Infectious Diseases...Dokončeno
-
Johns Hopkins UniversityUkončeno
-
National Institute of Allergy and Infectious Diseases...Dokončeno
-
François SpertiniUniversity of OxfordDokončenoTuberkulóza | Mycobacterium Tuberculosis, ochrana protiŠvýcarsko
-
Region SkaneNáborLatentní tuberkulóza | Mycobacterium tuberculosis | Přetrvávající infekceŠvédsko
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHAktivní, ne náborInfekce Mycobacterium TuberculosisGabon, Keňa, Jižní Afrika, Tanzanie, Uganda
-
Assistance Publique - Hôpitaux de ParisDokončenoKostní a osteoartikulární infekce způsobené MDR kmeny M. TuberculosisFrancie
Klinické studie na Screening for Tuberculosis
-
Chengdu CoenBiotech Co., LtdBeijing Friendship Hospital; Beijing Chest Hospital, Capital Medical UniversityDokončeno
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Shanghai Public Health Clinical Center; Air Force Military Medical University... a další spolupracovníciDokončeno
-
Forendo Pharma LtdRichmond Pharmacology LimitedDokončenoRelativní biologická dostupnostSpojené království
-
GlaxoSmithKlineCorixa CorporationDokončenoTuberkulóza (TB)Spojené státy
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.NáborLatentní tuberkulózní infekceČína
-
South Dakota State UniversityUniversity of Missouri-Columbia; Ohio State University; Michigan State University a další spolupracovníciDokončenoZabezpečení potravin | Nutriční hodnota
-
Mary LacyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Aktivní, ne nábor
-
Universidad Miguel Hernandez de ElcheAktivní, ne náborDeprese | Poruchy nálady | Úzkostné poruchy | Emocionální porucha | Příznaky deprese | Úzkostné poruchy a příznakyŠpanělsko
-
Bill & Melinda Gates Medical Research InstituteBill and Melinda Gates Foundation; Wellcome TrustNáborTuberkulózaIndonésie, Keňa, Malawi, Mosambik, Jižní Afrika, Vietnam, Zambie